These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11521119)

  • 1. Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy.
    Hammond GL; Rabe T; Wagner JD
    Am J Obstet Gynecol; 2001 Aug; 185(2 Suppl):S24-31. PubMed ID: 11521119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity.
    Phillips A; Hahn DW; McGuire JL
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New knowledge in the physiology of hormonal contraceptives.
    Lobo RA; Stanczyk FZ
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of the androgenicity of progestins in hormonal therapy in women.
    Linn ES
    Clin Ther; 1990; 12(5):447-55. PubMed ID: 2268868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacology of newer progestogens.
    Kuhl H
    Drugs; 1996 Feb; 51(2):188-215. PubMed ID: 8808163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Side effects of third generation progestagens].
    Sitruk-ware R
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):295-300. PubMed ID: 12318229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis.
    Heald A; Selby PL; White A; Gibson JM
    Am J Obstet Gynecol; 2000 Sep; 183(3):593-600. PubMed ID: 10992179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulin.
    Phillips A; Hahn DW; McGuire JL
    Steroids; 1990 Aug; 55(8):373-5. PubMed ID: 2122551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study.
    Wells M; Sturdee DW; Barlow DH; Ulrich LG; O'Brien K; Campbell MJ; Vessey MP; Bragg AJ
    BMJ; 2002 Aug; 325(7358):239. PubMed ID: 12153918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
    Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
    Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progestins and breast cancer: an epidemiologic review.
    Staffa JA; Newschaffer CJ; Jones JK; Miller V
    Fertil Steril; 1992 Mar; 57(3):473-91. PubMed ID: 1740192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins.
    Phillips A; Demarest K; Hahn DW; Wong F; McGuire JL
    Contraception; 1990 Apr; 41(4):399-410. PubMed ID: 2335104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormonal contraception].
    Van Cauwenberge JR
    Rev Med Liege; 1992 May; 47(5):221-36. PubMed ID: 1604074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.